Literature DB >> 28617566

Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.

Daniel L C Costa1,2, Juliana B Diniz2, Guaraci Requena2,3, Marinês A Joaquim2, Christopher Pittenger4, Michael H Bloch4, Euripedes C Miguel2, Roseli G Shavitt2.   

Abstract

OBJECTIVE: To evaluate the efficacy of serotonin reuptake inhibitor (SRI) augmentation with N-acetylcysteine (NAC), a glutamate modulator and antioxidant medication, for treatment-resistant obsessive-compulsive disorder (OCD).
METHODS: We conducted a randomized, double-blind, placebo-controlled, 16-week trial of NAC (3,000 mg daily) in adults (aged 18-65 years) with treatment-resistant OCD, established according to DSM-IV criteria. Forty subjects were recruited at an OCD-specialized outpatient clinic at a tertiary hospital (May 2012-October 2014). The primary outcome measure was the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores. To evaluate the variables group, time, and interaction effects for Y-BOCS scores at all time points, we used nonparametric analysis of variance with repeated measures. Secondary outcomes were the severity scores for anxiety, depression, specific OCD symptom dimensions, and insight.
RESULTS: Both groups showed a significant reduction of baseline Y-BOCS scores at week 16: the NAC group had a reduction of 4.3 points (25.6 to 21.3), compared with 3.0 points (24.8 to 21.8) for the placebo group. However, there were no significant differences between groups (P = .92). Adding NAC was superior to placebo in reducing anxiety symptoms (P = .02), but not depression severity or specific OCD symptom dimensions. In general, NAC was well tolerated, despite abdominal pain being more frequently reported in the NAC group (n [%]: NAC = 9 [60.0], placebo = 2 [13.3]; P < .01).
CONCLUSIONS: Our trial did not demonstrate a significant benefit of NAC in reducing OCD severity in treatment-resistant OCD adults. Secondary analysis suggested that NAC might have some benefit in reducing anxiety symptoms in treatment-resistant OCD patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01555970. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28617566     DOI: 10.4088/JCP.16m11101

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.

Authors:  Fenghua Li; Maartje C Welling; Jessica A Johnson; Catherine Coughlin; Jillian Mulqueen; Ewgeni Jakubovski; Samantha Coury; Angeli Landeros-Weisenberger; Michael H Bloch
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-12-03       Impact factor: 2.576

2.  Mitochondrial modulators for obsessive-compulsive and related disorders: a systematic review and meta-analysis.

Authors:  Taro Kishi; Kenji Sakuma; Nakao Iwata
Journal:  Transl Psychiatry       Date:  2022-06-28       Impact factor: 7.989

Review 3.  The Potential of N-Acetylcysteine for Treatment of Trichotillomania, Excoriation Disorder, Onychophagia, and Onychotillomania: An Updated Literature Review.

Authors:  Debra K Lee; Shari R Lipner
Journal:  Int J Environ Res Public Health       Date:  2022-05-24       Impact factor: 4.614

Review 4.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

Review 5.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

6.  Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial.

Authors:  Renata de Melo Felipe da Silva; Andre R Brunoni; Stephan Goerigk; Marcelo Camargo Batistuzzo; Daniel Lucas da Conceição Costa; Juliana Belo Diniz; Frank Padberg; Giordano D'Urso; Eurípedes Constantino Miguel; Roseli Gedanke Shavitt
Journal:  Neuropsychopharmacology       Date:  2021-01-15       Impact factor: 7.853

7.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

Review 8.  Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment.

Authors:  Naomi A Fineberg; Annemieke M Apergis-Schoute; Matilde M Vaghi; Paula Banca; Claire M Gillan; Valerie Voon; Samuel R Chamberlain; Eduardo Cinosi; Jemma Reid; Sonia Shahper; Edward T Bullmore; Barbara J Sahakian; Trevor W Robbins
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

9.  Inflammation, Obsessive-Compulsive Disorder, and Related Disorders.

Authors:  Jeffrey Meyer
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 10.  N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks).

Authors:  Gerry K Schwalfenberg
Journal:  J Nutr Metab       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.